Project Echo for PWS

ECHO 4 PWS: Cardiac Concerns

When: Thursday, August 15, 2024 at 5:00 PM EST

Where: Virtual/Zoom Video
This series is for health care providers only

Register below for our next ECHO 4 PWS webinar, “Cardiac Concerns with Dr. Jim Loker.”

PWSA | USA's - ECHO 4 PWS Health Care Provider Series

PWSA | USA launched our new Health Care Provider Project ECHO Series, ECHO 4 PWS, in 2023. We are proud to offer this opportunity to health care professionals who work with patients affected by Prader-Willi syndrome (PWS) and to be the first PWS organization to implement Project ECHO® in the United States.

Our next healthcare ECHO topic will focus on Cardiac Concerns presented by Jim Loker, MD, Clinical Professor, Department of Pediatric and Adolescent Medicine at Western Michigan University, followed by a 20-minute case study on PWS (speaker to be determined).

PWSA | USA’s Health Care Provider Project ECHO Series will touch on a wide range of healthcare topics in the PWS space and will be available for all health professionals across our network including (but not limited to): Geneticists, Pediatric Endocrinologists, Neonatologists, Nurses, Pediatricians, Endocrinologists, Psychiatrists, Psychologists, Social Workers, Occupational Therapists, Pulmonologists, Orthopedic Surgeons, Dieticians, Physiotherapists, Speech and Language Therapists, Medical Students and Professional Caregivers.

While this ECHO series is only for health care providers to attend, recordings of the webinars are available for our PWS families to view HERE.

Scroll below to find more ECHO 4 PWS webinar opportunities.

Speaker

Jim Loker, MD, Clinical Professor, Department of Pediatric and Adolescent Medicine at Western Michigan University

Dr. James Loker is a Clinical Professor in the Department of Pediatric and Adolescent Medicine. He is Board Certified in Pediatric Cardiology. He is employed with the Bronson Healthcare Group. He is a graduate of Kansas State University with a BS in Biology in May 1978. He is a graduate of St. Mary’s of the Plains College with a BA in Biology in May 1978. He also has a MA in Cardiopulmonary Physiology from the University of Kansas in May 1982. He earned his MD from the University of Kansas Medical Center in May 1986. He completed his residency in Pediatrics from the University of Indiana Medical Center-Riley Hospital for Children in May 1989. He completed a fellowship in Pediatric Cardiology also from the University of Indian Medical Center-Riley Hospital for Children in May 1992.

LEarn More about PWS Research

Soleno Therapeutics Submits New Drug Application to FDA for PWS Treatment

Soleno Therapeutics Submits New Drug Application to FDA for PWS Treatment

On June 28, 2024, Soleno Therapeutics announced the company officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DCCR (diazoxide choline) extended-release tablets. This new treatment targets Prader-Willi syndrome (PWS) in individuals aged 4 and older with hyperphagia. CEO Anish Bhatnagar, M.D., says, “Submission of the DCCR NDA to […]

Help Needed: Caregivers of Children with Prader-Willi Syndrome and Repetitive Verbal Behavior

Help Needed: Caregivers of Children with Prader-Willi Syndrome and Repetitive Verbal Behavior

Kasey Bedard, PhD, and her team at The Chicago School are seeking caregivers of children diagnosed with Prader-Willi Syndrome (PWS) who exhibit repetitive verbal behavior for a research study at The Chicago School. This study, part of a dissertation project, aims to test interventions that caregivers can implement at home. Study Details: – Duration: 2-3 […]

Fueling Hope: Aardvark Therapeutics’ $85M Boost Powers Breakthrough PWS Treatment

Fueling Hope: Aardvark Therapeutics’ $85M Boost Powers Breakthrough PWS Treatment

Aardvark Therapeutics has just hit a major milestone with an exciting $85 million Series C financing round! Led by Decheng Capital, with additional participation from several investors, including PWSA | USA, this funding is set to drive the development of ARD-101, a groundbreaking treatment for hyperphagia in Prader-Willi syndrome patients. ARD-101 showed promising early trial […]

Scroll to top